The deal with a company owned by Embraer gives Beta Technologies an additional source of revenue as it develops its own electric aircraft. By Niraj Chokshi Two companies racing to develop electric ...

This new investment supports BETA’s continued momentum certifying, producing and deploying all-electric aircraft and infrastructure, serving both commercial and military customers across cargo, ...

Read Seven Days’ November 5, 2025, cover story on Beta here. Vermont electric aviation startup Beta Technologies raked in more than $1 billion on Tuesday as it debuted on the New York Stock Exchange ...

Beta Technologies (BETA) is drawing strong investor interest ahead of its stock market debut, signaling renewed confidence in the electric aircraft sector after several years of skepticism following ...

(Reuters) -Electric aircraft maker Beta Technologies is expected to price its initial public offering at $34 per share, which is above its marketed range, Bloomberg News reported on Monday, citing ...

BETA Technologies is following a vertically integrated model similar to Tesla’s, starting with niche markets (cargo, defense) before expanding into passenger aviation. BETA's robust order backlog, ...

In this hilarious video, we dive into the chaos and confusion that ensues when kids don't understand that it's just a beta version of Battlefield 6. Watch as young gamers experience epic moments, ...

Oct 15 (Reuters) - Electric aircraft maker Beta Technologies said in a regulatory filing on Wednesday that it was aiming for a U.S. listing valuing the company at about $7.22 billion. Vermont-based ...

Beta Technologies has a partnership with GE Aerospace IPO market reopens for high-growth startups Beta's aircraft used by US military and FAA Sept 29 (Reuters) - Electric aircraft maker Beta ...

Two new studies point in opposite directions. A large new study conducted in Spain and Italy found that beta blockers, drugs often used to slow the heart rate and lower blood pressure, did not provide ...

A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack— doesn’t benefit the vast majority of patients and may contribute to a higher risk of ...